158 related articles for article (PubMed ID: 22403550)
1. Association of Basal hyperglucagonemia with impaired glucagon counterregulation in type 1 diabetes.
Farhy LS; Chan A; Breton MD; Anderson SM; Kovatchev BP; McCall AL
Front Physiol; 2012; 3():40. PubMed ID: 22403550
[TBL] [Abstract][Full Text] [Related]
2. Models of glucagon secretion, their application to the analysis of the defects in glucagon counterregulation and potential extension to approximate glucagon action.
Farhy LS; McCall AL
J Diabetes Sci Technol; 2010 Nov; 4(6):1345-56. PubMed ID: 21129329
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic network control of glucagon secretion and counterregulation.
Farhy LS; McCall AL
Methods Enzymol; 2009; 467():547-581. PubMed ID: 19897107
[TBL] [Abstract][Full Text] [Related]
4. System-level control to optimize glucagon counterregulation by switch-off of α-cell suppressing signals in β-cell deficiency.
Farhy LS; McCall AL
J Diabetes Sci Technol; 2009 Jan; 3(1):21-33. PubMed ID: 20046648
[TBL] [Abstract][Full Text] [Related]
5. Amplification of pulsatile glucagon counterregulation by switch-off of alpha-cell-suppressing signals in streptozotocin-treated rats.
Farhy LS; Du Z; Zeng Q; Veldhuis PP; Johnson ML; Brayman KL; McCall AL
Am J Physiol Endocrinol Metab; 2008 Sep; 295(3):E575-85. PubMed ID: 18577688
[TBL] [Abstract][Full Text] [Related]
6. Optimizing reduction in basal hyperglucagonaemia to repair defective glucagon counterregulation in insulin deficiency.
Farhy LS; McCall AL
Diabetes Obes Metab; 2011 Oct; 13 Suppl 1(0 1):133-43. PubMed ID: 21824267
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of glucagon secretion.
Young A
Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
[TBL] [Abstract][Full Text] [Related]
8. Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia.
Rizza RA; Cryer PE; Gerich JE
J Clin Invest; 1979 Jul; 64(1):62-71. PubMed ID: 36413
[TBL] [Abstract][Full Text] [Related]
9. Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion.
Bolli G; de Feo P; Compagnucci P; Cartechini MG; Angeletti G; Santeusanio F; Brunetti P; Gerich JE
Diabetes; 1983 Feb; 32(2):134-41. PubMed ID: 6337896
[TBL] [Abstract][Full Text] [Related]
10. The role of intramyocellular lipids during hypoglycemia in patients with intensively treated type 1 diabetes.
Bernroider E; Brehm A; Krssak M; Anderwald C; Trajanoski Z; Cline G; Shulman GI; Roden M
J Clin Endocrinol Metab; 2005 Oct; 90(10):5559-65. PubMed ID: 15998784
[TBL] [Abstract][Full Text] [Related]
11. Role of hepatic glycogen breakdown in defective counterregulation of hypoglycemia in intensively treated type 1 diabetes.
Kishore P; Gabriely I; Cui MH; Di Vito J; Gajavelli S; Hwang JH; Shamoon H
Diabetes; 2006 Mar; 55(3):659-66. PubMed ID: 16505228
[TBL] [Abstract][Full Text] [Related]
12. Defective activation of skeletal muscle and adipose tissue lipolysis in type 1 diabetes mellitus during hypoglycemia.
Enoksson S; Caprio SK; Rife F; Shulman GI; Tamborlane WV; Sherwin RS
J Clin Endocrinol Metab; 2003 Apr; 88(4):1503-11. PubMed ID: 12679430
[TBL] [Abstract][Full Text] [Related]
13. Glucose counterregulation, hypoglycemia, and intensive insulin therapy in diabetes mellitus.
Cryer PE; Gerich JE
N Engl J Med; 1985 Jul; 313(4):232-41. PubMed ID: 2861565
[TBL] [Abstract][Full Text] [Related]
14. Impact of C-Peptide Status on the Response of Glucagon and Endogenous Glucose Production to Induced Hypoglycemia in T1DM.
Zenz S; Mader JK; Regittnig W; Brunner M; Korsatko S; Boulgaropoulos B; Magnes C; Raml R; Narath SH; Eller P; Augustin T; Pieber TR
J Clin Endocrinol Metab; 2018 Apr; 103(4):1408-1417. PubMed ID: 29408994
[TBL] [Abstract][Full Text] [Related]
15. Impaired hormonal responses to hypoglycemia in spontaneously diabetic and recurrently hypoglycemic rats. Reversibility and stimulus specificity of the deficits.
Powell AM; Sherwin RS; Shulman GI
J Clin Invest; 1993 Dec; 92(6):2667-74. PubMed ID: 8254023
[TBL] [Abstract][Full Text] [Related]
16. Effects of insulin treatment without and with recurrent hypoglycemia on hypoglycemic counterregulation and adrenal catecholamine-synthesizing enzymes in diabetic rats.
Inouye KE; Yue JT; Chan O; Kim T; Akirav EM; Park E; Riddell MC; Burdett E; Matthews SG; Vranic M
Endocrinology; 2006 Apr; 147(4):1860-70. PubMed ID: 16396986
[TBL] [Abstract][Full Text] [Related]
17. Role of epinephrine-mediated beta-adrenergic mechanisms in hypoglycemic glucose counterregulation and posthypoglycemic hyperglycemia in insulin-dependent diabetes mellitus.
Popp DA; Shah SD; Cryer PE
J Clin Invest; 1982 Feb; 69(2):315-26. PubMed ID: 6120181
[TBL] [Abstract][Full Text] [Related]
18. Lilly lecture 1988. Glucose counterregulation and its impact on diabetes mellitus.
Gerich JE
Diabetes; 1988 Dec; 37(12):1608-17. PubMed ID: 3056759
[TBL] [Abstract][Full Text] [Related]
19. Leptin acts in the brain to influence hypoglycemic counterregulation: disparate effects of acute and recurrent hypoglycemia on glucagon release.
Reno CM; Ding Y; Sherwin R
Am J Physiol Endocrinol Metab; 2015 Dec; 309(12):E960-7. PubMed ID: 26506851
[TBL] [Abstract][Full Text] [Related]
20. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
Nauck MA; Heimesaat MM; Behle K; Holst JJ; Nauck MS; Ritzel R; Hüfner M; Schmiegel WH
J Clin Endocrinol Metab; 2002 Mar; 87(3):1239-46. PubMed ID: 11889194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
